CMS Relationship With Manufacturers Has Improved, But Questions Remain
Executive Summary
The relationship between CMS and drug manufacturers is improving through earlier communication regarding coverage decisions and emphasis on common interests, according to CMS Director-Coverage Analysis Group Steven Phurrough
You may also be interested in...
CMS Splits Coverage With Evidence Development Into Two Categories
Medicare is offering added flexibility to pay for research-related expenses that arise in the clinical trials conducted for a Part B national coverage decision, under revisions to Medicare's coverage with evidence development policy, released July 12
FDA/CMS Collaborations May Sidetrack Drug Development, Patient Access
Manufacturers seeking simultaneous pathways for product approval and Medicare coverage determinations could trigger "endless loops of information requirements" during premarket development, according to Kay Holcombe, a senior policy advisor for Genzyme
Medicare Rx Data May Be Difficult To Interpret, Merck Exec Cautions
Drawing conclusions about drug safety and outcomes from Medicare prescription drug data needs to be done with caution, Merck VP-Outcomes Research & Management Marc Berger told a Centers for Medicare & Medicaid Services "Open Door Forum" June 13